Gabapentin is a medication used to treat epilepsy, neuropathic pain, hot flashes, and restless legs syndrome. In epilepsy, it may be used for those with partial seizures. It is recommended as one of a number of first line medications for the treatment of neuropathic pain in diabetic neuropathy, postherpetic neuralgia, and central neuropathic pain.
Gabapentin was originally marketed under the brand name Neurontin and since it became generic, it has been marketed under many other brand names. An extended-release formulation of gabapentin for once-daily administration was introduced in 2011 for postherpetic neuralgia under the brand name Gralise.
Gabapentin is used primarily to treat seizures and neuropathic pain. It is also commonly prescribed for many off-label uses, such as treatment of anxiety disorders, insomnia, and bipolar disorder. There are, however, concerns regarding the quality of the trials conducted and evidence for some such uses, especially in the case of its use as a mood stabilizer in bipolar disorder.
According to this study, over the next five years the Gabapentin market will register a 1.6% CAGR in terms of revenue, the global market size will reach US$ 1550 million by 2024, from US$ 1430 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Gabapentin business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Gabapentin market by product type, application, key manufacturers and key regions and countries.
This study considers the Gabapentin value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Capsule
Tablet
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Epilepsy
Neuropathic Pain
Restless Legs Syndrome
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Pfizer
Depomed
TEVA
Mylan
Arbor Pharma
Novartis
Apotex
Sun Pharmaceutical
Aurobindo Pharma
Intas
Amneal
Marksans Pharma
Glenmark
Alkem
Jiangsu Enhua
Jiangsu Hengrui
Sailike
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Gabapentin consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Gabapentin market by identifying its various subsegments.
Focuses on the key global Gabapentin manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Gabapentin with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Gabapentin submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
